M. Ozen Et Al. , "Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010
Ozen, M. Et Al. 2010. Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15 .
Ozen, M., Aksoy, S., Dizdar, O., Dede, D. S., Dogan, E., Arslan, C., ... Gullu, I. H.(2010). Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.. JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15.
Ozen, M. Et Al. "Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.," JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010
Ozen, M. Et Al. "Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15, 2010
Ozen, M. Et Al. (2010) . "Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.." JOURNAL OF CLINICAL ONCOLOGY , vol.28, no.15.
@article{article, author={M. Ozen Et Al. }, title={Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2010}